Etodolac Capsules USP 300 mg + Etodolac
Phase 1Completed 0 watching 0 views this week💤 Quiet
33
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Fasting
Conditions
Fasting
Trial Timeline
Oct 1, 2012 → Dec 1, 2012
NCT ID
NCT01746719About Etodolac Capsules USP 300 mg + Etodolac
Etodolac Capsules USP 300 mg + Etodolac is a phase 1 stage product being developed by Ipca Laboratories for Fasting. The current trial status is completed. This product is registered under clinical trial identifier NCT01746719. Target conditions include Fasting.
Hype Score Breakdown
Clinical
10
Activity
5
Company
10
Novelty
3
Community
2
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01746719 | Phase 1 | Completed |
| NCT01749228 | Phase 1 | Completed |
Competing Products
20 competing products in Fasting
Other Products from Ipca Laboratories
Metoprolol Succinate ER Tablets 50 mg + 'TOPROL-XL®' ER Tablets 50 mgPhase 1
33
Indomethacin Extended-Release Capsules USP 75 mg + Indomethacin Extended Release Capsules USP 75 mgPhase 1
33
Ondansetron Tablets USP 8 mg + Ondansetron HydrochloridePhase 1
33
Risperidone Tablet 1 mg + RisperidonePhase 1
33
Etodolac Capsules USP 300 mg + EtodolacPhase 1
33